Spotlight Innovation Inc. (OTCMKTS:STLT) Files An 8-K Other Events
Item 8.01 Other Events.
On June 21, 2017, Spotlight Innovation Inc. (the Company) entered
into a Sponsored Research Agreement (the Agreement) with The
Brigham and Womens Hospital Inc. (BWH) to support research
directed by BWH professor Kevin Hodgetts aimed at developing safe
and effective drugs to treat patients with spinal muscular
atrophy.
The Company will provide to BWH an aggregate of $200,000 in
funding support for the research project. The Company shall
sponsor BWHs research project for a period of one (1) year,
unless sooner terminated by either party upon forty-five days
advance written notice to the terms of the Agreement.
About Spotlight Innovation Inc. (OTCMKTS:STLT)
Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The Company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. and Memcine Pharmaceuticals, Inc. Through its subsidiary, Celtic Biotech Iowa, Inc., it develops a range of drug candidates, such as Crotoxin, Cardiotoxin, VRCTC310 and Crotamine. Through its subsidiary, Memcine Pharmaceuticals, Inc., it offers Immunoplex.
